Boehringer Ingelheim has established a research alliance with Vanderbilt University and the cancer drug discovery laboratory of Professor Stephen W. Fesik, Ph.D., the Orrin H. Ingram, II Chair in Cancer Research and Professor of Biochemistry, Pharmacology, and Chemistry.
The aim of the new collaboration is the research and development of small molecule inhibitors of oncogenic Ras for the treatment of cancer.
Searching for more deal information? Current Partnering offers the following options:
|
Under the terms of the agreement, the research capabilities of Vanderbilt University and Boehringer Ingelheim will be brought together in a multi-year research programme focusing on the development of small molecule inhibitors of Ras.
Further details of the agreement are not disclosed.
For further deal information visit Current Agreements (subscription required)
Related
Scorecard: Top partnering deals by value in 2014
View: Top pharmaceutical companies
View: Top biotech companies
Reports: Browse our extensive deal making report portfolio
